Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMO-8400 in Relapsed/Refractory DLBCL With MyD88 L265P Mutation
NCT02252146Phase 2Completed
- Sponsor
- Aceragen, Inc.
- Start
- Jun 2014
- Primary completion
- Dec 2016
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of bazlitoran in diffuse large B-cell lymphoma (DLBCL), sponsored by Aceragen, Inc.. Started Jun 2014; status: completed.
02
Drugs
bazlitoran
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02252146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02252146.